Exenatide Drug Card PDF

Preview

Summary

Atnidiabetic medication exenatide drug facts and teaching...

Description

Student Name: Samantha Mendoza Classiication: Antidiabetics Generic Name: Exenatide Expected Pharmacological Action: Medical deinition:Reduces fasting and postprandial glucose levels in type 2 diabetes by stimulating insulin production in response to elevated glucose levels, inhibiting glucagon release after meals, and slowing gastric emptying; Lay terminology: Used to regulate blood sugar in type 2 diabetes. Usual Dose: 5 mcg/dose in 1.2-mL preilled pen (60 doses); 10 mcg/dose in 2.4-mL preilled pen (60 doses) Usual routes: SQ Therapeutic Uses:

Expected Common Adverse Eects:

Type 2 Diabetes Mellitus

-

Headache

-

Nervousness

-

Excessive sweating

Adverse Eects Requiring Nursing Action: Adverse Eects Pancreatitis

Action: Prevention/Assessment/Intervention -

Hypoglycemia

-

Stop medication Assess for s/s of pancreatitis, includes abdominal pain, fever, nausea, vomiting Check for abnormal lab test: lipase or amylase Stop medication Assess blood sugar level Assess for s/s of hypoglycemia

Likely Medication/Food Interactions: -

Acetaminophen: May decrease acetaminophen concentration. Give acetaminophen at least 1 hour before or 4 hours after exenatide injection. Digoxin, lovastatin: May decrease concentrations of these drugs. Monitor patient. Sulfonylureas: May increase the risk of hypoglycemia. Reduce sulfonylurea dose as needed, and monitor patient closely. Warfarin: May increase INR and increase bleeding risk when administered together. Monitor INR frequently, especially when starting drug or changing dosage.

Administration/Interventions/Evaluation of Eectiveness/Laboratory Work -

Contraindicated in patients hypersensitive to drug or its components. Serious reactions (anaphylaxis, angioedema) have been reported. If hypersensitivity occurs, discontinue drug.

-

Black Box Warning: Extended-release form is contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) and in patients with multiple endocrine neoplasia syndrome type 2. Decrease blood glucose level; May increase INR

Patient Education: What will the safe nurse teach the client to DO or expect or report? -

Explain to patient taking extended-release exenatide the risk and signs and symptoms of thyroid tumors (mass in the neck, dysphagia, dyspnea, persistent hoarseness). Advise patient that drug may decrease appetite, food intake, and body weight, and that these changes don’t warrant a change in dosage. Advise patient to seek immediate medical care if unexplained, persistent, severe abdominal pain, with or without vomiting, occurs. Inform patient receiving extended-release form about risk of serious injection-site reactions and to report signs and symptoms (erythema, pain, drainage, skin color changes) immediately. Stress importance of proper storage (refrigeration), infection prevention, and timing of exenatide dose in relation to other oral drugs.

Citations:

Lippincott Williams & Wilkins. (2020). Nursing2020 Drug Handbook. Philadelphia....